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BACKGROUND
Patients who are chronically infected with hepatitis C virus (HCV) and who do not 
have a sustained virologic response after treatment with regimens containing 
direct-acting antiviral agents (DAAs) have limited retreatment options.
METHODS
We conducted two phase 3 trials involving patients who had been previously treated 
with a DAA-containing regimen. In POLARIS-1, patients with HCV genotype 1 
infection who had previously received a regimen containing an NS5A inhibitor 
were randomly assigned in a 1:1 ratio to receive either the nucleotide polymerase 
inhibitor sofosbuvir, the NS5A inhibitor velpatasvir, and the protease inhibitor 
voxilaprevir (150 patients) or matching placebo (150 patients) once daily for 12 weeks. 
Patients who were infected with HCV of other genotypes (114 patients) were en-
rolled in the sofosbuvir–velpatasvir–voxilaprevir group. In POLARIS-4, patients 
with HCV genotype 1, 2, or 3 infection who had previously received a DAA regimen 
but not an NS5A inhibitor were randomly assigned in a 1:1 ratio to receive sofos-
buvir–velpatasvir–voxilaprevir (163 patients) or sofosbuvir–velpatasvir (151 patients) 
for 12 weeks. An additional 19 patients with HCV genotype 4 infection were en-
rolled in the sofosbuvir–velpatasvir–voxilaprevir group.
RESULTS
In the three active-treatment groups, 46% of the patients had compensated cirrhosis. 
In POLARIS-1, the rate of sustained virologic response was 96% with sofosbuvir–
velpatasvir–voxilaprevir, as compared with 0% with placebo. In POLARIS-4, the 
rate of response was 98% with sofosbuvir–velpatasvir–voxilaprevir and 90% with 
sofosbuvir–velpatasvir. The most common adverse events were headache, fatigue, 
diarrhea, and nausea. In the active-treatment groups in both trials, the percentage 
of patients who discontinued treatment owing to adverse events was 1% or lower.
CONCLUSIONS
Sofosbuvir–velpatasvir–voxilaprevir taken for 12 weeks provided high rates of sus-
tained virologic response among patients across HCV genotypes in whom treatment 
with a DAA regimen had previously failed. (Funded by Gilead Sciences; POLARIS-1 
and POLARIS-4 ClinicalTrials.gov numbers, NCT02607735 and NCT02639247.)
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The majority of patients who are chronically infected with hepatitis C virus (HCV) can now be successfully treated 
with drugs that directly target viral replication.1,2 
Combination regimens of direct-acting antiviral 
agents (DAAs) provide rates of sustained viro-
logic response exceeding 90%, regardless of HCV 
genotype, disease stage, or treatment history.3 
The proportion of patients who do not have a 
sustained virologic response to treatment with 
approved regimens is small, but given the size of 
the infected population — estimates range up to 
150 million people worldwide4 — the absolute 
number of such patients is substantial and will 
increase as more patients are treated for HCV 
infection. There are no approved retreatment op-
tions for patients who have previously received a 
regimen containing an NS5A inhibitor.5 These 
patients, who represent the majority of patients 
with recent treatment failures, are of particular 
concern because the resistance-associated sub-
stitutions that are selected by NS5A inhibitors 
maintain viral fitness long after the end of the 
failed treatment.
Sofosbuvir is a nucleotide analogue HCV NS5B 
polymerase inhibitor that, in combination with 
other DAAs, is approved for the treatment of 
HCV infection of all genotypes.6-8 Velpatasvir is 
an HCV NS5A inhibitor with pangenotypic po-
tency.9 The fixed-dose combination of sofosbuvir 
and velpatasvir provided high rates of sustained 
virologic response in phase 3 clinical trials and 
has recently been approved for the treatment of 
patients with HCV infection of any genotype, 
with or without cirrhosis, regardless of whether 
they have received previous treatment with inter-
feron-based therapy.10,11 Voxilaprevir (formerly 
GS-9857, Gilead Sciences) is a pangenotypic in-
hibitor of the HCV NS3–NS4A protease.12-14 In 
phase 2 trials, the combination of sofosbuvir, 
velpatasvir, and voxilaprevir was effective in a 
broad range of patients with chronic HCV in-
fection.15-18
We conducted two phase 3 trials to assess the 
efficacy and safety of the fixed-dose combina-
tion of sofosbuvir, velpatasvir, and voxilaprevir 
for 12 weeks in patients who were chronically 
infected with HCV of any genotype, including 
patients with compensated cirrhosis, who have 
previously received unsuccessful treatment with 
DAA-based regimens.
Me thods
Trial Oversight
The two trials were approved by the institutional 
review board or independent ethics committee at 
each participating site and were conducted in 
compliance with the Declaration of Helsinki, 
Good Clinical Practice guidelines, and local 
regulatory requirements. The trials were de-
signed and conducted by the sponsor (Gilead 
Sciences) in collaboration with the principal in-
vestigators, in accordance with the protocols, 
which are available with the full text of this 
article at NEJM.org. The sponsor collected the 
data, monitored trial conduct, and performed 
the statistical analyses. Independent data and 
safety monitoring committees reviewed the prog-
ress of the trials. All the authors had access to 
the data and assumed responsibility for the in-
tegrity and completeness of the reported data 
and the fidelity of the trials to the protocols. The 
initial draft of the manuscript was prepared by a 
writer employed by Gilead Sciences and by the 
primary investigators (the first and last authors) 
with input from all the authors.
Patients
We used identical eligibility criteria for the two 
trials, with the exception that POLARIS-1 enrolled 
only patients whose previous treatment included 
an NS5A inhibitor and POLARIS-4 enrolled pa-
tients who had been previously treated with any 
DAA regimen that did not include an NS5A in-
hibitor (with the exception that those who had 
received only a protease inhibitor with peginter-
feron and ribavirin were not included, since these 
patients have approved retreatment options). 
Patients had to have had virologic failure after 
completing previous treatment of at least 4 weeks’ 
duration; patients who discontinued owing to 
adverse events or who had virologic failure be-
cause of nonadherence to treatment were not 
enrolled. All patients provided written informed 
consent. The full eligibility criteria for both trials 
are provided in the Supplementary Appendix, 
available at NEJM.org.
Trial Design
In POLARIS-1, patients were enrolled at 108 sites 
in the United States, Canada, New Zealand, Aus-
tralia, France, Germany, and the United Kingdom 
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from November 2015 through May 2016. Patients 
with HCV genotype 1 infection (with a target of 
having at least 30% of the sample made up of 
patients with compensated cirrhosis) were random-
ly assigned in a 1:1 ratio to receive sofosbuvir–
velpatasvir–voxilaprevir or matched placebo for 
12 weeks; randomization was stratified accord-
ing to cirrhosis status. The investigators, patients, 
and study personnel were unaware of the study-
group assignments for patients with genotype 1 
infection until after the post-treatment week 4 
visit. All patients who were infected with HCV of 
other genotypes or an indeterminate genotype, 
regardless of whether they had cirrhosis, were 
enrolled in the sofosbuvir–velpatasvir–voxilapre-
vir group, since patients with non–genotype 1 
infection comprise a comparatively small propor-
tion of those who have virologic failure after 
treatment with a DAA-based regimen. Patients 
received either a fixed-dose combination tablet 
containing 400 mg of sofosbuvir, 100 mg of vel-
patasvir, and 100 mg of voxilaprevir or a match-
ing placebo tablet, administered orally once daily 
for 12 weeks. Patients who were randomly as-
signed to the placebo group were eligible for 12 
weeks of subsequent treatment with sofosbuvir–
velpatasvir–voxilaprevir.
In POLARIS-4, patients were enrolled at 101 
sites in the United States, Canada, New Zealand, 
Australia, France, Germany, and the United King-
dom from January through May 2016. In this 
open-label trial, patients with HCV genotype 1, 
2, or 3 infection were assigned in a 1:1 ratio to 
receive either sofosbuvir–velpatasvir–voxilaprevir 
or sofosbuvir–velpatasvir once daily for 12 weeks; 
randomization was stratified according to HCV 
genotype and cirrhosis status. Patients who were 
infected with HCV of any other genotype were 
assigned to receive sofosbuvir–velpatasvir–voxil-
aprevir for 12 weeks.
Assessments
For both trials, screening assessments included 
measurement of the serum HCV RNA level, 
IL28B genotyping, and standard laboratory and 
clinical testing. HCV RNA levels were measured 
with the use of the COBAS AmpliPrep/COBAS 
TaqMan HCV Quantitative Test, version 2.0, with 
a lower limit of quantification of 15 IU per milli-
liter. IL28B genotype was determined by poly-
merase chain reaction amplification of the single-
nucleotide polymorphism rs12979860, with the 
use of TaqMan MGB probes.
The Abbott RealTime HCV genotype II assay 
was used to determine HCV genotype at screen-
ing. HCV genotype and subtype were subsequent-
ly determined by analysis of NS3, NS5A, and 
NS5B sequences obtained by deep sequencing 
with the use of the Basic Local Alignment Search 
Tool (BLAST); these results were used in the 
analyses.
Deep sequencing of the NS3, NS5A, and NS5B 
coding regions was performed on samples ob-
tained from all the patients at baseline and from 
those patients with virologic failure at the time 
of failure. Sequences that were obtained at the 
time of virologic failure were compared with 
sequences from baseline samples to detect resis-
tance-associated substitutions that arose in as-
sociation with treatment. We report resistance-
associated substitutions that were present in 
more than 15% of sequence reads.
End Points
For both trials, the primary efficacy end point 
was a sustained virologic response, defined as a 
serum HCV RNA level lower than 15 IU per milli-
liter 12 weeks after the end of treatment in pa-
tients who were enrolled and received at least 
one dose of active treatment or placebo. Patients 
whose HCV RNA levels were not assessed at 12 
weeks after treatment for any reason were clas-
sified as not having had a sustained virologic 
response, with the exception of those who had 
an HCV RNA level lower than 15 IU per milliliter 
both before and after post-treatment week 12; a 
sustained virologic response at post-treatment 
week 12 was imputed for these patients. The 
primary safety end point was the proportion of 
patients who stopped taking active treatment or 
placebo prematurely owing to adverse events.
The secondary efficacy end points were the 
percentage of patients with an HCV RNA level 
lower than 15 IU per milliliter at 4 and 24 weeks 
after the end of treatment, the percentage of pa-
tients with an HCV RNA level lower than 15 IU 
per milliliter during treatment, the change in 
HCV RNA level from baseline (day 1), and the 
proportion of patients with virologic failure (de-
fined as a confirmed HCV RNA level of at least 
15 IU per milliliter after two consecutive mea-
surements showing HCV RNA levels lower than 
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15 IU per milliliter, or an increase in the HCV 
RNA level of more than 1 log10 from the nadir 
during the treatment period). In addition, we 
report results for the secondary objective of an 
assessment of the emergence of viral resistance 
to the study drugs. Evaluation of other second-
ary objectives for POLARIS-1 — the character-
ization of the steady-state pharmacokinetics of 
sofosbuvir, velpatasvir, and voxilaprevir, and an 
evaluation of the efficacy and safety of deferred 
treatment with 12 weeks of sofosbuvir–velpatas-
vir–voxilaprevir in the placebo group — are be-
yond the scope of the current report.
Statistical Analysis
In both trials, the primary efficacy analysis was 
designed to test for the superiority of the rate of 
sustained virologic response achieved among pa-
tients receiving sofosbuvir–velpatasvir–voxilapre-
vir or sofosbuvir–velpatasvir over a performance 
goal of 85%, with the use of a two-sided exact 
one-sample binomial test at the 0.05 signifi-
cance level for POLARIS-1 and at the 0.025 sig-
nificance level for POLARIS-4, on the basis of 
the Bonferroni adjustment for two primary effi-
cacy tests. The planned enrollment of 280 pa-
tients in the sofosbuvir–velpatasvir–voxilaprevir 
group in POLARIS-1 and of 205 patients in the 
sofosbuvir–velpatasvir–voxilaprevir group and 175 
in the sofosbuvir–velpatasvir group in POLARIS-4 
were calculated to provide more than 90% power 
to detect an advantage of 10 percentage points in 
the rate of sustained virologic response over the 
performance goal of 85%, which was based on 
the efficacy of the combination of sofosbuvir–
velpatasvir–voxilaprevir in phase 2 trials. Confi-
dence intervals for the efficacy rates according 
to subgroup were not adjusted for multiplicity. 
POLARIS-4 was not powered for a comparison 
between sofosbuvir–velpatasvir–voxilaprevir and 
sofosbuvir–velpatasvir, and no statistical com-
parisons between the groups were planned or 
performed. The results with regard to the sec-
ondary end points and objectives were summa-
rized.
R esult s
Patients
Of the 520 patients who underwent screening 
for POLARIS-1, 416 were enrolled, and 415 be-
gan the active treatment or placebo (Table S1 
and Fig. S1 in the Supplementary Appendix). In 
total, we enrolled 300 patients with HCV geno-
type 1 infection, 5 with genotype 2 infection, 78 
with genotype 3 infection, 22 with genotype 4 
infection, 1 with genotype 5 infection, 8 with 
genotype 6 infection, and 1 with infection with 
HCV of unknown genotype. Of the 300 patients 
with HCV genotype 1 infection, 150 were ran-
domly assigned to the sofosbuvir–velpatasvir–
voxilaprevir group, and 150 were assigned to the 
placebo group. The other 114 patients with 
non–genotype 1 HCV infection at screening were 
enrolled in the sofosbuvir–velpatasvir–voxilapre-
vir group. Of these patients, 1 with HCV geno-
type 4 infection never received treatment.
Of the 397 patients who underwent screening 
for POLARIS-4, 333 were enrolled and treated: 
144 patients with HCV genotype 1 infection, 64 
with genotype 2 infection, 106 with genotype 3 
infection, and 19 with genotype 4 infection 
(Table S2 and Fig. S2 in the Supplementary Ap-
pendix). No patients with HCV genotype 5 or 6 
infection were enrolled. In total, 163 patients 
were randomly assigned to receive sofosbuvir–
velpatasvir–voxilaprevir (78 patients with geno-
type 1 infection, 31 with genotype 2 infection, 
and 54 with genotype 3 infection), and 151 were 
assigned to receive sofosbuvir–velpatasvir (66 with 
genotype 1 infection, 33 with genotype 2 infec-
tion, and 52 with genotype 3 infection). Per 
protocol, all 19 patients with HCV genotype 4 
infection were enrolled in the sofosbuvir–velpat-
asvir–voxilaprevir group.
The demographic and baseline clinical char-
acteristics of the patients in both trials are 
shown in Table 1. In each of the three active-
treatment groups, the percentage of patients with 
compensated cirrhosis was 46%. In POLARIS-1, 
the most common NS5A inhibitors used in pre-
vious unsuccessful treatment were ledipasvir 
(55% of patients), daclatasvir (23%), and ombit-
asvir (13%). In POLARIS-4, 85% of patients had 
received sofosbuvir as a part of previous unsuc-
cessful treatment.
Efficacy
POLARIS-1
Among the patients who had previously been 
treated with a regimen containing an NS5A in-
hibitor, the overall rate of sustained virologic 
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Characteristic POLARIS-1 POLARIS-4
Placebo 
(N = 152)
Sofosbuvir–Velpatasvir– 
Voxilaprevir 
(N = 263)
Sofosbuvir–Velpatasvir– 
Voxilaprevir 
(N = 182)
Sofosbuvir– 
Velpatasvir 
(N = 151)
Mean age (range) — yr 59 (29–80) 58 (27–84) 57 (24–85) 57 (24–80)
Male sex — no. (%) 121 (80) 200 (76) 143 (79) 114 (75)
Race — no. (%)†
White 124 (82) 211 (80) 160 (88) 131 (87)
Black 22 (14) 38 (14) 16 (9) 13 (9)
Asian 6 (4) 8 (3) 2 (1) 4 (3)
Other 0 6 (2) 4 (2) 3 (2)
HCV genotype — no. (%)
1 150 (99) 150 (57) 78 (43) 66 (44)
1a 117 (77) 101 (38) 54 (30) 44 (29)
1b 31 (20) 45 (17) 24 (13) 22 (15)
Other 2 (1) 4 (2) 0 0
2 0 5 (2) 31 (17) 33 (22)
3 0 78 (30) 54 (30) 52 (34)
4 0 22 (8) 19 (10) 0
5 0 1 (<1) 0 0
6 2 (1) 6 (2) 0 0
Unknown 0 1 (<1) 0 0
IL28B genotype
CC 27 (18) 47 (18) 33 (18) 29 (19)
CT 93 (61) 165 (63) 107 (59) 95 (63)
TT 32 (21) 51 (19) 42 (23) 27 (18)
Cirrhosis — no. (%) 51 (34) 121 (46) 84 (46) 69 (46)
HCV RNA level — log10 IU/ml 6.3±0.6 6.3±0.7 6.3±0.6 6.3±0.7
ALT level — U/liter 74±84 89±72 84±65 85±68
Previous HCV DAAs received — no. (%)
NS5A inhibitor plus NS3 inhibitor with or 
without NS5B inhibitor
62 (41) 83 (32) 0 0
NS5A inhibitor plus NS5B inhibitor 80 (53) 161 (61) 0 0
NS5A inhibitor 9 (6) 18 (7) 0 0
NS5B inhibitor plus NS3 inhibitor 1 (1)‡ 0 46 (25) 38 (25)
NS5B inhibitor 0 1 (<1)‡ 134 (74) 109 (72)
NS3 inhibitor 0 0 2 (1)‡§ 3 (2)‡§
None 0 0 0 1 (<1)‡¶
No. of previous HCV treatment regimens — no. (%)
1 102 (67) 160 (61) 111 (61) 91 (60)
≥2 50 (33) 103 (39) 71 (39) 60 (40)
Most recent HCV treatment response — no. 
(%)
No response 10 (7) 20 (8) 7 (4) 12 (8)
Relapse 125 (82) 224 (85) 171 (94) 131 (87)
Other 17 (11) 19 (7) 4 (2) 8 (5)
*  Plus–minus values are means ±SD. ALT denotes alanine aminotransferase, DAA direct-acting antiviral agent, and HCV hepatitis C virus.
†  Race was reported by the patient.
‡  The patient or patients were enrolled in error.
§  Previous DAA treatment with only NS3 inhibitors was an exclusion criterion in POLARIS-4, since these patients have approved retreatment options.
¶  This patient had previously received only interferon and ribavirin, not HCV DAAs.
Table 1. Baseline Demographic and Clinical Characteristics of the Patients in the Two Trials.*
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response in the sofosbuvir–velpatasvir–voxila-
previr group was 96% (95% confidence interval 
[CI], 93 to 98), which was significantly superior 
to the prespecified performance goal of 85% 
(P<0.001) (Fig. 1 and Table 2). Of the 253 pa-
tients with a sustained virologic response at 
week 12 after treatment, 249 returned for the 
post-treatment week 24 visit. All 249 patients 
had a sustained virologic response at that time. 
None of the patients who received placebo had a 
sustained virologic response. The HCV RNA 
levels and changes from baseline at each visit 
through the end of treatment are provided in 
Table S3 in the Supplementary Appendix.
The rates of sustained virologic response were 
96% (95% CI, 90 to 99) among patients with 
HCV genotype 1a infection, 100% (95% CI, 92 to 
100) among those with genotype 1b infection, 
100% (95% CI, 48 to 100) among those with 
genotype 2 infection, 95% (95% CI, 87 to 99) 
among those with genotype 3 infection, 91% 
(95% CI, 71 to 99) among those with genotype 4 
infection, and 100% (95% CI, 54 to 100) among 
those with genotype 6 infection. The single pa-
Figure 1. Rates of Sustained Virologic Response According to Subgroup.
The position of the square indicates the rate of sustained virologic response, defined as a virologic response at 12 
weeks after the end of treatment, in each subgroup; the horizontal lines indicate 95% confidence intervals. The ver-
tical lines represent the overall rate of sustained virologic response in each treatment group. The subgroup analysis 
did not include patients who withdrew consent (two patients in POLARIS-1) or were lost to follow-up (one patient in 
POLARIS-1 and two patients in POLARIS-4). BMI denotes body-mass index (the weight in kilograms divided by the 
square of the height in meters), and HCV hepatitis C virus.
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tient with HCV genotype 5 infection had a sus-
tained virologic response. Overall, the rate of 
sustained virologic response was 99% (95% CI, 
95 to 100) among patients who did not have cir-
rhosis and 93% (95% CI, 87 to 97) among those 
who had cirrhosis. Of the 56 patients with geno-
type 3 infection and cirrhosis, 52 had a sustained 
virologic response (93%; 95% CI, 83 to 98).
Among the 263 patients who received sofos-
buvir–velpatasvir–voxilaprevir, 10 did not have a 
sustained virologic response. Of these 10 pa-
tients, 7 had virologic failure: 1 (<1%) had viro-
Type of Response POLARIS-1* POLARIS-4
Sofosbuvir–Velpatasvir–
Voxilaprevir 
(N = 263)
Sofosbuvir–Velpatasvir–
Voxilaprevir 
(N = 182)
Sofosbuvir– 
Velpatasvir 
(N = 151)
no. of patients/total no. (%)
HCV RNA level <15 IU/ml
During treatment
At 2 wk 149/263 (57) 114/182 (63) 85/151 (56)
At 4 wk 243/262 (93) 161/182 (88) 137/151 (91)
At 8 wk 262/262 (100) 182/182 (100) 149/151 (99)
At 12 wk 260/261 (100) 180/182 (99) 149/150 (99)
After end of treatment
At 4 wk 257/263 (98) 179/182 (98) 138/151 (91)
At 12 wk†
Any genotype 253/263 (96) 178/182 (98) 136/151 (90)
Genotype 1a 97/101 (96) 53/54 (98) 39/44 (89)
Genotype 1b 45/45 (100) 23/24 (96) 21/22 (95)
Other genotype 1 4/4 (100) 0 0
Genotype 2 5/5 (100) 31/31 (100) 32/33 (97)
Genotype 3 74/78 (95) 52/54 (96) 44/52 (85)
Genotype 4 20/22 (91) 19/19 (100) 0
Genotype 5 1/1 (100) 0 0
Genotype 6 6/6 (100) 0 0
Unknown 1/1 (100) 0 0
Virologic breakthrough during treatment 1/263 (<1) 0 1/151 (1)
Relapse after the end of treatment 6/261 (2)‡ 1/182 (1) 14/150 (9)§
Loss to follow-up 1/263 (<1) 2/182 (1) 0
Withdrawal of consent 2/263 (1) 0 0
Death 0 1/182 (1) 0
*  None of the patients who received placebo in POLARIS-1 had an HCV RNA level of less than 15 IU per milliliter at any 
time point.
†  This category indicates a sustained virologic response (i.e., an HCV RNA level lower than 15 IU per milliliter 12 weeks 
after the end of treatment).
‡  Of the 6 patients with relapse, 1 had HCV genotype 1a infection, 4 had genotype 3a infection, and 1 had genotype 4a 
infection.
§  Of the 14 patients with relapse, 5 had HCV genotype 1a infection, 1 had genotype 1b infection, and 8 had genotype 3a 
infection.
Table 2. Response Rates during and after the Treatment Period.
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logic breakthrough during treatment, and 6 (2%) 
had virologic relapse after the end of treatment. 
The patient with virologic breakthrough had low 
plasma concentrations of GS-331007 (the chief 
sofosbuvir metabolite), velpatasvir, and voxila-
previr at weeks 8 and 12, which was suggestive 
of nonadherence. Two patients receiving sofos-
buvir–velpatasvir–voxilaprevir withdrew consent, 
one after completing treatment and having a 
virologic response 4 weeks after the end of treat-
ment and another after taking four doses of 
study drug (as described below). One other pa-
tient was lost to follow-up after week 8 of treat-
ment. The characteristics of the 7 patients who 
had virologic failure are provided in Table S5 in 
the Supplementary Appendix.
POLARIS-4
Among the patients who had previously been 
treated with a regimen containing any DAA ex-
cept an NS5A inhibitor, the overall rate of sus-
tained virologic response was 98% (95% CI, 95 to 
99) among those who received sofosbuvir–velpat-
asvir–voxilaprevir, which was significantly supe-
rior to the prespecified performance goal of 85% 
(P<0.001) (Table 2 and Fig. 1). The rate of sus-
tained virologic response among the patients 
who received sofosbuvir–velpatasvir was 90% 
(95% CI, 84 to 94), which was not significantly 
superior to the prespecified performance goal of 
85% (P = 0.09). The HCV RNA levels and changes 
from baseline at each study visit through the end 
of treatment are provided in Table S4 in the 
Supplementary Appendix.
Among patients without cirrhosis, the rate of 
sustained virologic response was 98% among 
those receiving sofosbuvir–velpatasvir–voxilapre-
vir and 94% among those receiving sofosbuvir–
velpatasvir, as compared with 98% and 86%, 
respectively, among patients with cirrhosis. Ta-
ble 2 shows rates of sustained virologic response 
according to HCV genotype. Of the 177 patients 
in the sofosbuvir–velpatasvir–voxilaprevir group 
and the 136 patients in the sofosbuvir–velpatas-
vir group who had a sustained virologic response 
at post-treatment week 12, a total of 173 and 133 
patients, respectively, returned for the post-
treatment week 24 visit, and all the patients had 
a sustained virologic response at that time. One 
patient in the sofosbuvir–velpatasvir–voxilapre-
vir group did not attend the post-treatment week 
12 visit; however, this patient returned at post-
treatment week 24 and had an HCV RNA level 
lower than 15 IU per milliliter. In accordance 
with the prespecified analysis plan, a sustained 
virologic response at post-treatment week 12 
was imputed for this patient.
Among the 333 patients who were treated in 
POLARIS-4, 19 did not have a sustained viro-
logic response — 4 patients (3%) in the sofosbu-
vir–velpatasvir–voxilaprevir group and 15 patients 
(10%) in the sofosbuvir–velpatasvir group. Of 
the 4 patients in the sofosbuvir–velpatasvir–
voxilaprevir group who did not have a sustained 
virologic response, 1 (1%) had a virologic relapse 
by week 4 of follow-up, 1 died (see below), and 
2 were lost to follow-up. Among the 15 patients 
in the sofosbuvir–velpatasvir group who did not 
have a sustained virologic response, 14 (9%) had 
a relapse after completing treatment and 1 (1%) 
had virologic breakthrough during treatment. 
Eight of the 14 patients who had a relapse had 
HCV genotype 3a infection, 5 had genotype 1a 
infection, and 1 had genotype 1b infection (Ta-
ble S6 in the Supplementary Appendix).
Viral Resistance Testing
Among the 248 patients who received sofosbuvir–
velpatasvir–voxilaprevir in POLARIS-1 and for 
whom viral sequence data were available, 205 
(83%) had viral substitutions associated with 
resistance to NS3 inhibitors or NS5A inhibitors 
at baseline that were present in at least 15% of 
sequence reads. Of these patients, 97% (199 of 
205) had a sustained virologic response, as com-
pared with 98% of patients without resistance-
associated substitutions at baseline (Table S7 in 
the Supplementary Appendix). Among the 6 pa-
tients who had a relapse, 1 patient with HCV 
genotype 4 infection had development of the 
NS5A Y93H resistance-associated substitution 
(Table S5 in the Supplementary Appendix).
In POLARIS-4, 49% of enrolled patients had 
baseline viral substitutions associated with re-
sistance to NS3 inhibitors or NS5A inhibitors. 
The rates of sustained virologic response among 
patients for whom viral sequence data were 
available and who received sofosbuvir–velpatasvir–
voxilaprevir for 12 weeks was 100% (83 of 83) 
among those with baseline resistance-associated 
substitutions and 99% (85 of 86) among those 
without baseline resistance-associated substitu-
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tions, as compared with 90% (63 of 70) and 89% 
(67 of 75), respectively, among those with and 
those without resistance-associated substitutions 
in the sofosbuvir–velpatasvir group (Table S8 in 
the Supplementary Appendix). The single patient 
in the sofosbuvir–velpatasvir–voxilaprevir group 
who had a relapse did not have any resistance-
associated substitutions at either baseline or the 
time of relapse. Among the 14 patients in the 
sofosbuvir–velpatasvir group who had a relapse, 
11 had resistance-associated substitutions, most 
of which were in the NS5A gene at amino acid 
position 93 (Table S6 in the Supplementary Ap-
pendix).
Safety
One patient who received sofosbuvir–velpatasvir–
voxilaprevir in POLARIS-1 discontinued treatment 
prematurely because of an adverse event. This 
patient, a 59-year-old woman with a history of 
hypertension, started therapy with ramipril on 
study day 11 and discontinued sofosbuvir–velpat-
asvir–voxilaprevir treatment on day 12 because 
of angioedema. Three patients who received 
placebo in POLARIS-1 discontinued because of 
adverse events. In POLARIS-4, 1 patient, a 63-year-
old woman in the sofosbuvir–velpatasvir group, 
discontinued treatment on study day 49 because 
of worsening of headache. None of the patients 
in POLARIS-4 who received sofosbuvir–velpatas-
vir–voxilaprevir discontinued treatment prema-
turely because of adverse events.
A total of seven serious adverse events oc-
curred among 5 patients (2%) who received 
sofosbuvir–velpatasvir–voxilaprevir in POLARIS-1 
(Table 3, and Table S9 in the Supplementary Ap-
pendix). In the placebo group, 7 patients had 
one serious adverse event each. In POLARIS-4, 
4 patients (2%) receiving sofosbuvir–velpatasvir–
voxilaprevir and 4 patients (3%) receiving sofos-
buvir–velpatasvir had one serious adverse event 
each (Table S10 in the Supplementary Appendix). 
Across both trials, no single serious adverse event 
occurred in more than 1 patient. One patient, a 
61-year-old man, died from an illicit drug over-
dose 2 days after completing the 12 weeks of treat-
ment with sofosbuvir–velpatasvir–voxilaprevir.
In POLARIS-1, 78% of patients who received 
sofosbuvir–velpatasvir–voxilaprevir had adverse 
events, as compared with 70% of patients who 
received placebo (Table 3). The most common 
events in the sofosbuvir–velpatasvir–voxilaprevir 
group were headache (25% of patients), fatigue 
(21%), diarrhea (18%), and nausea (14%), and the 
most common events in the placebo group were 
fatigue (20%), headache (17%), diarrhea (12%), 
and dizziness (9%). In POLARIS-4, the incidence 
of adverse events was 77% among patients who 
received sofosbuvir–velpatasvir–voxilaprevir and 
74% among those who received sofosbuvir–vel-
patasvir. The most common events among pa-
tients who received sofosbuvir–velpatasvir–voxi-
laprevir were headache (27%), fatigue (24%), and 
diarrhea (20%), and the most common events 
among those who received sofosbuvir–velpatasvir 
were headache (28%), fatigue (28%), and nausea 
(8%). The majority of events of diarrhea were 
mild in severity; the incidence of grade 2 diar-
rhea was low (1 to 3%). There were no events of 
grade 3 or 4 diarrhea. The grade 3 and 4 adverse 
events in POLARIS-1 and POLARIS-4 are pre-
sented in Tables S11 and S12 in the Supplemen-
tary Appendix.
The incidence of grade 3 and 4 laboratory 
abnormalities was 5% and 2%, respectively, 
among patients receiving sofosbuvir–velpatasvir–
voxilaprevir in POLARIS-1, as compared with 
12% and 2% among those receiving placebo 
(Table 3, and Table S13 in the Supplementary 
Appendix). In POLARIS-4, the incidence of grade 
3 and 4 laboratory abnormalities was 5% and less 
than 1%, respectively, among patients receiving 
sofosbuvir–velpatasvir–voxilaprevir, as compared 
with 6% and 1% among patients receiving sofos-
buvir–velpatasvir (Table 3, and Table S14 in the 
Supplementary Appendix). None of the grade 3 
and 4 elevations in lipase and creatine kinase 
levels were accompanied by clinical evidence of 
pancreatitis or myopathy, respectively.
Discussion
In these international phase 3 trials, 12 weeks of 
treatment with sofosbuvir–velpatasvir–voxilapre-
vir resulted in high rates of sustained virologic 
response among patients with and patients with-
out compensated cirrhosis who had HCV of any 
genotype and who had not had a sustained viro-
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Event POLARIS-1 POLARIS-4
Placebo 
(N = 152)
Sofosbuvir–Velpatasvir– 
Voxilaprevir 
(N = 263)†
Sofosbuvir–Velpatasvir– 
Voxilaprevir 
(N = 182)
Sofosbuvir–
Velpatasvir 
(N = 151)
number of patients (percent)
Any adverse event 107 (70) 206 (78) 140 (77) 111 (74)
Discontinuation of treatment because of adverse event 3 (2) 1 (<1) 0 1 (1)
Serious adverse event 7 (5) 5 (2) 4 (2) 4 (3)
Death 0 0 1 (1) 0
Adverse events occurring in ≥5% of patients in any 
group
Headache 26 (17) 66 (25) 50 (27) 43 (28)
Fatigue 30 (20) 56 (21) 43 (24) 43 (28)
Diarrhea 19 (12) 47 (18) 36 (20) 7 (5)
Nausea 12 (8) 37 (14) 22 (12) 12 (8)
Asthenia 9 (6) 20 (8) 10 (5) 9 (6)
Insomnia 8 (5) 19 (7) 12 (7) 3 (2)
Dizziness 14 (9) 11 (4) 9 (5) 2 (1)
Back pain 8 (5) 11 (4) 12 (7) 8 (5)
Arthralgia 8 (5) 8 (3) 9 (5) 4 (3)
Abdominal pain 3 (2) 7 (3) 3 (2) 9 (6)
Irritability 4 (3) 7 (3) 4 (2) 8 (5)
Laboratory abnormality
Hemoglobin level <10 g/dl 1 (1) 2 (1) 2 (1) 1 (1)
Lymphocyte count <500/mm3 2 (1) 0 1 (1) 1 (1)
Neutrophil count <750/mm3 0 1 (<1) 0 2 (1)
Platelet count <50,000/mm3 0 2 (1) 3 (2) 2 (1)
INR >1.5× ULN 2 (1) 0 0‡ 1 (1)‡
Alanine aminotransferase >5× ULN 3 (2) 0 1 (1) 0
Aspartate aminotransferase >5× ULN 7 (5) 2 (1) 0 0
Creatine kinase level ≥10× ULN 2 (1) 3 (1) 1 (1) 0
Glucose level >250 mg/dl 7 (5) 4 (2) 4 (2) 3 (2)
Lipase level >3× ULN 4 (3) 6 (2) 3 (2) 1 (1)
Total bilirubin level >2.5× ULN 0 1 (<1)§ 0 0
*  To convert the values for glucose to mmol per liter, multiply by 0.05551. INR denotes international normalized ratio, and ULN upper limit  
of the normal range.
†  Laboratory values are missing for 1 patient in POLARIS-1 who received sofosbuvir–velpatasvir–voxilaprevir and withdrew from the trial 12 
days into treatment.
‡  INR values are missing for 9 patients who received sofosbuvir–velpatasvir–voxilaprevir and for 4 patients who received sofosbuvir–velpatas-
vir in POLARIS-4.
§  This patient, a 36-year-old white man who had a grade 2 elevation in the total bilirubin level at baseline, had a transient grade 3 elevation 
during the first week of treatment. The alanine aminotransferase and aspartate aminotransferase levels for this patient were normal 
throughout treatment.
Table 3. Adverse Events, Discontinuations of Active Treatment or Placebo, and Hematologic Abnormalities.*
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logic response after previous treatment with 
regimens containing DAAs, including NS5A in-
hibitors. This population of patients has been 
underrepresented in clinical trials and has lim-
ited retreatment options. It should be noted that 
these trials involved only patients who had ob-
served virologic failure after having completed 
previous treatment; it excluded those who did 
not have a sustained virologic response as a 
result of nonadherence or those who had dis-
continued previous treatment owing to adverse 
events.
Because of their potency, NS5A inhibitors have 
been a common component of DAA regimens. 
Substitutions in the viral genome that confer 
resistance to NS5A inhibitors, unlike those that 
confer resistance to NS3 protease inhibitors and 
NS5B polymerase inhibitors, appear to maintain 
the viability of the virus after unsuccessful treat-
ment with an NS5A inhibitor–containing regi-
men and have been shown to have an effect on 
the rate of sustained virologic response in pre-
vious studies of DAA regimens.19 As expected, 
POLARIS-1 and POLARIS-4 enrolled a substan-
tial number of patients who had resistance- 
associated viral substitutions at baseline, but the 
presence of such substitutions had no discern-
ible effect on the rates of sustained virologic 
response with sofosbuvir–velpatasvir–voxila-
previr.
The incidence of adverse events among the 
patients who received sofosbuvir–velpatasvir–voxi-
laprevir was generally similar to the rates among 
patients who received placebo in POLARIS-1 and 
sofosbuvir–velpatasvir in POLARIS-4, except that 
more patients who received sofosbuvir–velpatas-
vir–voxilaprevir in POLARIS-1 had headache and 
more patients who received sofosbuvir–velpatas-
vir–voxilaprevir in both trials had mild-to-mod-
erate nausea and diarrhea, which are known 
effects of some NS3–NS4A protease inhibitors.20 
No patient interrupted treatment or discontin-
ued treatment prematurely as a result of these 
events.
The generalizability of these results may be 
limited by the small numbers of patients in some 
subpopulations, including those with genotype 3 
infection and cirrhosis and those infected with 
rarer genotypes, as well as by the fact that some 
patients did not receive previous treatment with 
commercially available regimens. Another limi-
tation that affects the generalizability of these 
trials is the small number of retreated patients 
who had treatment failure with the more recently 
approved HCV regimens that include velpatasvir 
or elbasvir. The results also cannot be general-
ized to patients who were excluded from the 
trials, such as those coinfected with hepatitis B 
virus or human immunodeficiency virus and 
those with decompensated cirrhosis.
In conclusion, these results show that daily 
treatment with the single-tablet regimen of 
sofosbuvir–velpatasvir–voxilaprevir for 12 weeks 
is highly effective for patients infected with HCV 
of any genotype, with or without compensated 
cirrhosis, who did not have a sustained virologic 
response after treatment with DAA-based regi-
mens, including NS5A inhibitors.
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